Human Anti-CD59 (clone 1E8) scFv-Fc Chimera (CAT#: VS-0125-FY58)

• Host Species
• Human

• Type
• Human IgG1, scFv-Fc

• Species Reactivity
• Human

• Clone
• clone 1E8

• Applications
• ELISA, Flow Cytometry, Complement-dependent cytolysis

• Related Disease
• Prostate cancer

• Purity
• >95% as determined by SDS-PAGE

• Format
• Liquid

• Concentration
• Please refer to the vial label for the specific concentration.

• Buffer
• PBS

• Preservative
• No preservatives

• Stabilizer
• No Stabilizers

• Sterility
• 0.2 μM filtered

• Storage
• Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

• Shipping
• Ice packs

• Application Notes
• The anti-CD59 single-chain antibody (scFv-Fc), known as 1E8 scFv-Fc, has the potential to serve as an effective adjuvant therapy in cancer treatment. By targeting CD59-expressing cancer cells, this recombinant antibody may enhance complement-dependent cytotoxicity (CDC), leading to increased tumor cell lysis and death. Given that CD59 is a key regulator of the complement system that inhibits complement-mediated cell death, the binding of 1E8 scFv-Fc to CD59 on the surface of tumor cells could activate the complement cascade. This activation may bolster the anti-tumor immune response, offering a promising avenue for improving cancer therapies.

• Alternative Names
• CD59 Molecule (CD59 Blood Group); CD59 Antigen P18-20 (Antigen Identified By Monoclonal Antibodies 16.3A5, EJ16, EJ30, EL32 And G344); CD59 Molecule, Complement Regulatory Protein; Membrane Attack Complex Inhibition Factor; Membrane Inhibitor Of Reactive Lysis; 20 KDa Homologous Restriction Factor; MEM43 Antigen; 1F5 Antigen; Protectin; HRF-20; MAC-IP; MIC11; MSK21; HRF20; MACIF; MIN1; MIN2; MIN3; MIRL; Surface Anitgen Recognized By Monoclonal Antibody 16.3A5

• Gene ID
• 966

• UniProt ID
• P13987

• Cellular Localization
• Cell membrane; Lipid-anchor, GPI-anchor
  Secreted

• Post Translation Modifications
• N- and O-glycosylated.
  Glycated.
  Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects.
  Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.
  Glycosylation at Thr40, Asn43, Lys66, Thr76, Thr77, Thr105, Ser106, and Thr111
  Modification sites at PhosphoSitePlus
  Glycosylation from GlyConnect CD59_HUMAN (79)
  Glycosylation from GlyGen 7 sites, 216 N-linked glycans (2 sites), 9 O-linked glycans (6 sites)

• Protein Refseq
• NP_000602.1; NP_001120695.1; NP_001120697.1; NP_001120698.1; NP_001120699.1

• Function
• Potent inhibitor of the complement membrane attack complex (MAC) action.
  Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore.
  This inhibitor appears to be species-specific.
  Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.

Secondary Antibody

• 2ND-029CQ
• Goat Anti-Human IgG Fc Antibody

Isotype Control

• MOB-200CQ
• Human IgG Fc Isotype Control Antibody

Select a product category from the dropdown menu below to view related products.